Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,963 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study.
Hoang T, Campbell TC, Zhang C, Kim K, Kolesar JM, Oettel KR, Blank JH, Robinson EG, Ahuja HG, Kirschling RJ, Johnson PH, Huie MS, Wims ME, Larson MM, Hernan HR, Traynor AM. Hoang T, et al. Among authors: robinson eg. Invest New Drugs. 2014 Feb;32(1):195-9. doi: 10.1007/s10637-013-9980-5. Epub 2013 Jun 1. Invest New Drugs. 2014. PMID: 23728919 Free PMC article. Clinical Trial.
A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study.
LoConte NK, Holen KD, Schelman WR, Mulkerin DL, Deming DA, Hernan HR, Traynor AM, Goggins T, Groteluschen D, Oettel K, Robinson E, Lubner SJ. LoConte NK, et al. Among authors: robinson e. Invest New Drugs. 2013 Aug;31(4):943-8. doi: 10.1007/s10637-012-9916-5. Epub 2012 Dec 21. Invest New Drugs. 2013. PMID: 23263993 Free PMC article. Clinical Trial.
Results from a prospective longitudinal survey of employment and work outcomes in newly diagnosed cancer patients during and after curative-intent chemotherapy: A Wisconsin Oncology Network study.
Tevaarwerk AJ, Kwekkeboom K, Buhr KA, Dennee A, Conkright W, Onitilo AA, Robinson E, Ahuja H, Kwong RW, Nanad R, Wiegmann DA, Chen K, LoConte NK, Wisinski KB, Sesto ME. Tevaarwerk AJ, et al. Among authors: robinson e. Cancer. 2021 Mar 1;127(5):801-808. doi: 10.1002/cncr.33311. Epub 2020 Nov 24. Cancer. 2021. PMID: 33231882 Free PMC article.
Reply to The effects of curative-intent cancer therapy on employment, work ability, and work limitations.
Tevaarwerk AJ, Kwekkeboom K, Buhr KA, Dennee A, Conkright W, Onitilo A, Robinson E, Ahuja H, Kwong RW, Nanad R, Wiegmann DA, Chen K, LoConte NK, Wisinski KB, Sesto ME. Tevaarwerk AJ, et al. Among authors: robinson e. Cancer. 2021 Aug 15;127(16):3033-3034. doi: 10.1002/cncr.33566. Epub 2021 Jun 18. Cancer. 2021. PMID: 34143434 Free article. No abstract available.
Triangulating evidence from the GALENOS living systematic review on trace amine-associated receptor 1 (TAAR1) agonists in psychosis.
Smith KA, Boyce N, Chevance A, Chiocchia V, Correll CU, Donoghue K, Ghodke N, Kambeu T, Malhi GS, Macleod M, Milligan L, Morgan J, Potts J, Robinson ESJ, Siafis S, Sommer IEC, Voelkl B, Salanti G, Cipriani A, Higgins JPT. Smith KA, et al. Among authors: robinson esj. Br J Psychiatry. 2024 Dec 23:1-9. doi: 10.1192/bjp.2024.237. Online ahead of print. Br J Psychiatry. 2024. PMID: 39710623
The 2024 small island developing states report of the Lancet Countdown on health and climate change.
Gordon-Strachan GM, Parker SY, Harewood HC, Méndez-Lázaro PA, Saketa ST, Parchment KF, Walawender M, Abdulkadri AO, Beggs PJ, Buss DF, Chodak RJ, Dasgupta S, De Santis O, Guthrie-Dixon NG, Hassan S, Kennard H, Maharaj SB, Marshall KG, McFarlane SR, McKenzie KS, Moradi-Lakeh M, Murphy M, Mycoo MA, Ng Shiu R, O'Hare MB, Oura CAL, Owfi F, Owfi A, Polson KA, Rabbaniha M, Robinson EJZ, Smith DC, Tabatabaei M, Tuiasosopo LL, Romanello M. Gordon-Strachan GM, et al. Among authors: robinson ejz. Lancet Glob Health. 2025 Jan;13(1):e146-e166. doi: 10.1016/S2214-109X(24)00421-2. Epub 2024 Dec 9. Lancet Glob Health. 2025. PMID: 39667387 Free article. Review. No abstract available.
The effect of percentage of time spent above different glucose levels on 90 days mortality of critically ill patients - A retrospective cohort study.
Statlender L, Robinson E, Grossman A, Duskin-Bitan H, Shochat T, Hellerman Itzhaki M, Fishman G, Singer P, Kagan I, Bendavid I. Statlender L, et al. Among authors: robinson e. Clin Nutr ESPEN. 2024 Nov 26;65:118-125. doi: 10.1016/j.clnesp.2024.11.024. Online ahead of print. Clin Nutr ESPEN. 2024. PMID: 39603345
2,963 results